$136.290
-0.286 (-0.21%)Zum Schluss
Umsatzquellen von TFX
Teleflex Incorporated (TFX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Vascular access, accounting for 43.2% of total sales, equivalent to $246.34M. Other significant revenue streams include Interventional and Surgical. Understanding this composition is critical for investors evaluating how TFX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitabilität und Margen von TFX
Evaluating the bottom line, Teleflex Incorporated maintains a gross margin of 58.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.61%, while the net margin is 3.30%. These profitability ratios, combined with a Return on Equity (ROE) of -0.70%, provide a clear picture of how effectively TFX converts its operational activities into shareholder value.
TFX im Vergleich zur Peergroup
In the context of the broader market, TFX competes directly with industry leaders such as HAE and MMSI. With a market capitalization of $5.77B, it holds a leading position in the sector. When comparing efficiency, TFX's gross margin of 58.16% stands against HAE's 56.98% and MMSI's 49.95%. Such benchmarking helps identify whether Teleflex Incorporated is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Teleflex Inc
The company has shown a gross margin of 58.16% in the latest quarter, which is relatively strong, although it has faced fluctuations in net income, including a recent loss of $8.15 million in Q1 2026.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.